2012 Medical Pharmacy & Oncology Trend ReportTM
Did you know that Lucentis, an injectable therapy for treating Macular Degeneration, is among the top five for drug spend per million lives covered under the medical benefit? In fact, specialty drugs now account for 25% of total spend. And this figure is expected to grow over 30% by 2016, with approximately half the specialty spend occurring on the medical benefit. Do you have the right tools and strategies to manage this spend?
Magellan Pharmacy Solutions' 2012 Medical Pharmacy & Oncology Trend Report provides the only source for trends and benchmarking statistics for injectables paid under the medical benefit. By surveying 50 top U.S. commercial health plans, representing nearly 160 million lives, we leverage three years of trend report benchmarking data and glean valuable insights to share with you.
On March 13, Michael Waterbury, President of ICORE, gave an insightful presentation of the significant findings of ICORE's 2012 Medical Pharmacy & Oncology Trend Report.
Below you'll find a link to a full recording of the webinar. With this on-demand version you can view it at any time, or share the link with any colleagues who might have missed it.